Renier Mendez, MD
Interventional Pain Medicine · Bayamon, PRNPI 1093804924
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,629 of the $2,207 with a category attached, or 73.8%. Medtronic accounts for 60.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $1,185 and has fallen 87.4% since, to $150 in 2025.
Across 36 payments — averaging $61.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Boston Scientific$617
- Biohaven Pharmaceuticals, Inc.$104
- Merck$100
- Collegium Pharmaceutical, Inc.$21
- Bsn Medical Inc$17
- plus $15 from 1 others
What the payments were for
- Travel & lodging$57826%
- Food & beverage$1,62974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 19 | $1,334 |
| Boston Scientific | 12 | $617 |
| Biohaven Pharmaceuticals, Inc. | 1 | $104 |
| Merck | 1 | $100 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Bsn Medical Inc | 1 | $17 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$477
- SYNCHROMEDII$153
- INCEPTIV$133
- NURTEC ODT$104
- PNEUMOVAX 23$100
How this compares
Too few interventional pain medicine providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tramadol Hcl | 447 | $1,891 |
| Oxycodone Hcl | 150 | $1,611 |
| Pregabalin | 17 | $681 |
| Betamethasone Sod Phos-AcetateBetamethasone Acetate,sod Phos | 13 | $645 |
| Gabapentin | 83 | $565 |
| Celecoxib | 39 | $551 |
| Naloxone Hcl | 26 | $390 |
| Ketorolac Tromethamine | 70 | $328 |
| Methylprednisolone Acetate | 18 | $299 |
| Lidocaine HclLidocaine Hcl/Pf | 15 | $42 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Bayamon
- Luis CummingsPonce$21K
- Dorian Lopez-BracettySan Juan$7K
- Amanda TroutSan Juan$6K
- Pedro Cabrera-BonetAguada$2K
- Arturo Perez CorreaCaguas$908
- Alejandro Porrata NievaSan Juan$375
- Robert CastroMayaguez$373
- Rafael AcevedoHormigueros$303
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.